The company said Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board, began a temporary medical leave of absence effective September 14, 2025.

1. 01

   The company said Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board, began a temporary medical leave of absence effective September 14, 2025.

2. 02

   The company said its Board of Directors, effective September 14, 2025, appointed Jacob S. Leach, President and Chief Operating Officer, as interim principal executive officer in addition to his existing duties.

3. 03

   Mark Foletta, Lead Independent Director, was appointed interim chairman of the Board, and Dexcom said Leach and Foletta will not receive any additional compensation for their interim appointments.

4. 04

   Dexcom said there is no arrangement or understanding between Leach and any other person under which he was selected as an officer, there are no family relationships between Leach and any of its directors or executive officers, and Leach has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.